These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 6429130)

  • 1. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants.
    Murphy DL; Garrick NA; Aulakh CS; Cohen RM
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):37-43. PubMed ID: 6735994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
    Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
    Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
    Norman TR; Burrows GD
    J Neural Transm Suppl; 1989; 28():53-63. PubMed ID: 2677243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoamine oxidase inhibitors: reversible and irreversible.
    Rudorfer MV
    Psychopharmacol Bull; 1992; 28(1):45-57. PubMed ID: 1609042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Indications for therapy using MAO inhibitors].
    Schmauss M; Erfurth A
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():2-6. PubMed ID: 2685853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible monoamine oxidase-A inhibitors in panic disorder.
    Bakish D; Saxena BM; Bowen R; D'Souza J
    Clin Neuropharmacol; 1993; 16 Suppl 2():S77-82. PubMed ID: 8313401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyramine and new monoamine oxidase inhibitor drugs.
    Simpson GM; de Leon J
    Br J Psychiatry Suppl; 1989 Oct; (6):32-7. PubMed ID: 2695125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of reversible monoamine oxidase inhibitors in depressive illness.
    Roth M; Guelfi JD
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():18-24. PubMed ID: 1394027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of MAO inhibitors: safety and future.
    Yamada M; Yasuhara H
    Neurotoxicology; 2004 Jan; 25(1-2):215-21. PubMed ID: 14697896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moclobemide: a reversible inhibitor of monoamine oxidase type A.
    Baldwin D; Rudge S
    Br J Hosp Med; 1993 Apr 7-20; 49(7):497-9. PubMed ID: 8490690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors.
    Ossowska G; Klenk-Majewska B; Danilczuk Z; Wróbel A; Zebrowska-Lupina I
    Pol J Pharmacol; 1999; 51(5):391-7. PubMed ID: 10817539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.